title: [Clinical evaluation of a line probe assay kit for the identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis].
abstract: BACKGROUND
  Multidrug resistance (MDR) involves resistance to both isoniazid and rifampicin, which makes the treatment of tuberculosis very difficult. Extensive drug resistance (XDR) occurs when, in addition to isoniazid and rifampicin resistance, the microorganisms are resistant to a fluoroquinolone and an injectable agent (e.g., kanamycin, amikacin, or capreomycin). Generally, drug susceptibility testing takes more than 3-4 weeks after the initial cultivation. There is an urgent need to identify methods that can rapidly detect both the presence of Mycobacterium tuberculosis and the status of drug resistance.
  
  
  OBJECTIVE
  This study was aimed at evaluating the line probe assay (LiPA; Nipro Co.), for the identification of Mycobacterium species and detection of mutations associated with antituberculous drugs.
  
  
  RESULTS
  We found that LiPA enabled the rapid identification of M. tuberculosis, M. avium, M. intracellulare, and M. kansasii. When the results of the LiPA and conventional drug susceptibility tests were compared, there was no difference in the susceptibility to rifampicin, pyrazinamide, and levofloxacin; however, there was a difference in the susceptibility to isoniazid.
  
  
  CONCLUSIONS
  Thus, LiPA can be used for the rapid identification of Mycobacterium species and the determination of susceptibility to drugs, which can help in the early initiation of appropriate treatment, leading to a reduction in infectiousness.
authors.affiliation: Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1, Habikino, Habikino-shi, Osaka 583-8588, Japan. tom_matsumoto@sutv.zaq.ne.jp
authors.forename: Tomoshige
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Hideo
authors.initials: H
authors.lastname: Ogata
authors.forename: Emiko
authors.initials: E
authors.lastname: Toyota
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Takefumi
authors.initials: T
authors.lastname: Saito
authors.forename: Akira
authors.initials: A
authors.lastname: Fujita
authors.forename: Toshinori
authors.initials: T
authors.lastname: Suetake
authors.forename: Kinuyo
authors.initials: K
authors.lastname: Chikamatsu
authors.forename: Kazue
authors.initials: K
authors.lastname: Mizuno
authors.forename: Satoshi
authors.initials: S
authors.lastname: Mitarai
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests / Q000295:instrumentation / Q000379:methods*; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000235:genetics / Q000302:isolation & purification*; D015242:Ofloxacin / Q000494:pharmacology; D011718:Pyrazinamide / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D064704:Levofloxacin; D015242:Ofloxacin; D007538:Isoniazid; D012293:Rifampin